STLNHealthcare · Medical Care FacilitiesThe 5 Wall Street analysts covering Starling Oncology, Inc. hold a median 12-month price target of $9 — +38.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Starling Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on STLN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +38.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | BTIG | Maintains | Buy | $8.00 → $9.00 |
| 9 July 2026 | BTIG | Maintains | Buy | — |
| 6 July 2026 | Lake Street | Initiates | Buy | $10 |
| 6 July 2026 | Lake Street | Initiates | Buy | — |
| 17 June 2026 | Needham | Maintains | Buy | — |
| 8 June 2026 | BTIG | Maintains | Buy | — |
| 13 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 13 Mar 2026 | Needham | Reiterates | Buy | — |
| 9 Mar 2026 | BTIG | Reiterates | Buy | — |
| 9 Mar 2026 | Needham | Reiterates | Buy | — |
| 25 Nov 2025 | Needham | Initiates | Buy | — |
| 21 Oct 2025 | BTIG | Reiterates | Buy | — |
| 16 July 2025 | B. Riley Securities | Initiates | Buy | — |
| 26 Feb 2024 | Jefferies | Assumes | Buy | $2.50 |
| 16 June 2023 | Guggenheim | Maintains | Buy | — |
| 20 Mar 2023 | Guggenheim | Maintains | Neutral | — |
| 11 Nov 2022 | Guggenheim | Maintains | Buy | — |
| 15 Aug 2022 | Jefferies | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STLN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 64% of US stocks
Cheaper than 99% of US stocks
Cheaper than 93% of US stocks
Higher than 80% of US stocks
Higher than 68% of US stocks
Higher than 17% of US stocks
Higher than 29% of US stocks
Higher than 23% of US stocks
Higher than 99% of US stocks
Higher than 27% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Starling Oncology, Inc. has a market value of $705.3M and an enterprise value of $769.0M.
Revenue in the twelve months to 30 June 2026: $587.2M. The latest quarter grew 34.6% year on year.
Net income over the same four quarters: −$36.3M, a −6.2% net margin.
Diluted earnings per share, trailing twelve months: $−0.30.
Free cash flow in the twelve months to 30 June 2026: −$3.3M.
Trailing P/E: −12.7×; forward P/E: 479.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Starling Oncology, Inc. employs 641 people — $916K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Starling Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cedar Grove Capital’s Q3 2026 update said it closed its long positions in MTY Food Group, uniQure, ClearPoint Neuro and Suja Life, and closed short positions in nine other companies. It also initiated a small tracking position in Zedcor while continuing due diligence.
Why it matters — The update mentions uniQure, but does not report any position in or development involving Starling Oncology.
Physician leaders from Starling Oncology highlighted recent and upcoming participation at major industry conferences, sharing clinical insights on value-based therapy delivery, clinical trial access, and integrated behavioral health in community oncology.
Why it matters — A STLN watcher would care because the company's physician leaders are raising its profile and sharing its clinical approach at prominent industry forums.
Starling Oncology received a BUY rating in a Seeking Alpha analysis, citing strong secular growth and expanding adoption of its oncology managed care services. The company raised its FY26 guidance to revenue growth of 31%, gross profit growth of 41%, and positive EBITDA and free cash flow, supported by its scalable delegation contract revenue model.
Why it matters — The raised FY26 guidance and expectations of positive EBITDA and free cash flow signal improving profitability and cash generation for STLN investors.
Starling Oncology announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the Wells Fargo Healthcare Conference in Boston on September 8, 2026, including a fireside chat from 4:30–5:05 p.m.
Why it matters — A STLN watcher would care because the company's top executives will present to investors at a major healthcare industry conference, offering visibility into the company.
Starling Oncology announced the launch of Starling Oncology Nexus, a proprietary technology platform designed to address NCCN compliance and streamline the fragmented, administratively burdensome prior authorization process for oncology providers. The company described Nexus as built to optimize provider engagement and accelerate high-quality care at scale.
Why it matters — STLN watchers would care because the launch introduces a proprietary technology offering that could support the company's value-based community oncology operations by easing administrative burdens and encouraging guideline compliance.
The 5 Wall Street analysts covering Starling Oncology, Inc. have a median 12-month price target of $9, with estimates ranging from $7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Starling Oncology, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Starling Oncology, Inc. 65 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Starling Oncology, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +38.2% from the last close, and Ticker Nerd's factor model ranks Starling Oncology, Inc. 65 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Starling Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $11 over the next 12 months.
Starling Oncology Inc. is a healthcare company focused on delivering specialized, value-based cancer care through a community-based oncology platform.
The most recent item we track (Seeking Alpha, 7 Oct 2026): "Cedar Grove Capital Q3 2026 Portfolio Update". Cedar Grove Capital’s Q3 2026 update said it closed its long positions in MTY Food Group, uniQure, ClearPoint Neuro and Suja Life, and closed short positions in nine other companies. It also initiated a small tracking position in Zedcor while continuing due diligence.
Starling Oncology Inc. is a healthcare company focused on delivering specialized, value-based cancer care through a community-based oncology platform. The company provides physician-led oncology services that include cancer diagnosis and treatment, in-house infusion, specialty pharmacy support, clinical trials, radiation oncology, transfusion services, and coordinated patient support. Its integrated model is designed to manage care across multiple touchpoints, helping patients navigate treatment with access to medication management, case coordination, and ongoing clinical assistance. Starling Oncology serves adult and senior cancer patients through clinics and affiliated care sites across several U.S. states, making it a significant provider in community oncology. The company’s current business is centered on combining advanced cancer therapies with accessible local care delivery for patients and payors.
CEO Dr. Daniel Virnich FACHE, M.B.A., M.D. · 641 employees · United States · https://starlingoncology.com
